KRAS and colorectal carcinoma: Notably, KRAS-driven glutamine metabolic rewiring is context-dependent: in pancreatic ductal adenocarcinoma (PDAC) models, mutant KRAS suppresses GLUD1 while upregulating GOT1 (167), whereas in CRC its expression remains unaltered.